SER AMEX
Serina Therapeutics, Inc.
1W: -6.2%
1M: -25.2%
3M: +0.5%
YTD: -5.8%
1Y: -62.7%
3Y: -92.4%
5Y: -94.3%
$1.96
+0.01 (+0.51%)
Weekly Expected Move ±11.0%
$2
$2
$2
$2
$2
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Smart Money Score
Moderate
50
Insider+$0.1M
Congress—
ETF Holdings—
Key Statistics
Market Cap$29.4M
52W Range1.22-5.83
Volume15,180
Avg Volume82,722
Beta0.03
Dividend—
Analyst Ratings
Company Info
CEOSteven A. Ledger
Employees16
SectorHealthcare
IndustryBiotechnology
IPO Date2018-11-28
Websiteserinatherapeutics.com
601 Genome Way
Huntsville, AL 35806
US
Huntsville, AL 35806
US
256 327 9630
About Serina Therapeutics, Inc.
Serina Therapeutics, Inc., a biotechnology firm, focuses on creating pharmaceutical treatments for neurological conditions and pain. Its primary investigational drug, SER 252, is a POZ conjugate intended for managing Parkinson's disease. The company is also developing SER 227 for prolonged pain relief, SER 214, another candidate for Parkinson's disease, and SER 228 to treat epilepsy. Beyond these, Serina Therapeutics leverages its POZ technology in producing ribonucleic acid (RNA) vaccines delivered via lipid nanoparticles for combating infectious diseases. This company was established in 2006 and is headquartered in Huntsville, Alabama.
Latest News
Serina Therapeutics, Inc. (NYSEAMERICAN:SER) Sees Significant Decline in Short Interest
12 Health Care Stocks Moving In Wednesday's Pre-Market Session
Serina Therapeutics wins NYSE approval; 2027 listing compliance deadline set
Serina Therapeutics GAAP EPS of -$1.91, revenue of $0.13M
12 Health Care Stocks Moving In Wednesday's Intraday Session
Recent Insider Trades
| Name | Type | Shares | Price | Date |
|---|---|---|---|---|
| Simon Farrell | A-Award | 30,500 | $2.17 | 2026-07-22 |
| Simon Farrell | 0 | — | 2026-07-22 | |
| Brannan Stephen K. | P-Purchase | 1,000 | $2.03 | 2026-07-07 |
| Venkatesan Jay | C-Conversion | 224,152 | $2.25 | 2026-06-17 |
| Venkatesan Jay | A-Award | 15,250 | $1.98 | 2026-06-17 |